- Home
- XSLL vs TTRX Comparison
XSLL vs TTRX Comparison
Compare XSLL & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XSLL | TTRX |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.3M | 281.2M |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | XSLL | TTRX |
|---|---|---|
| Price | $9.91 | $8.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 11.3K | ★ 128.6K |
| Earning Date | N/A | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.80 | $2.57 |
| 52 Week High | $10.00 | $11.69 |
Technical Indicators
Market Signals| Indicator | XSLL | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 53.65 |
| Support Level | N/A | $4.40 |
| Resistance Level | $10.00 | $10.48 |
| Average True Range (ATR) | 0.01 | 0.79 |
| MACD | -0.00 | -0.27 |
| Stochastic Oscillator | 10.00 | 42.38 |
Price Performance
Historical ComparisonAbout XSLL Xsolla SPAC 1 Class A Ordinary Shares
Xsolla SPAC 1 is a blank check company.
About TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.